Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

NCT07189325 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.

NCT NCT07189325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07189325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Lead sponsor
University Hospital, Montpellier
Phase
Phase 3
Overall status
Recruiting
Start date
June 15, 2026
Completion date
June 30, 2031
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-cd20 therapy, relapsing-remitting multiple sclerosis (rrms)